Nasdaq [1] |
AstraZeneca: FDA Panel Mostly Favorable in Diabetes Treatment Vote [1]
Nasdaq LONDON–AstraZeneca PLC (AZN.LN) Wednesday said most members of a U.S. Food and Drug Administration committee found its diabetes treatment [2] saxagliptin has an acceptable cardiovascular risk profile. The drug company said 13 of the 15 … AstraZeneca : FDA Panel Reviews Savor Study Results For Onglyza … [3]RTT News AstraZeneca Drug Gets US Orphan Designation, Key Cancer Drug Study Backed [4]London South East AstraZeneca share price: Immuno-oncology therapy granted orphan drug status [5]iNVEZZ all 84 news articles » [6] |
More details can be found at www.diabeteshowto.com [7]